DANIEL LOEWE • Institute of Bioprocess Engineering and Pharmaceutical Technology
(IBPT), Technische Hochschule Mittelhessen (THM) - University of Applied Sciences,
Giessen, Germany
KEVEN LOTHERT • Institute of Bioprocess Engineering and Pharmaceutical Technology
(IBPT), Technische Hochschule Mittelhessen (THM) - University of Applied Sciences,
Giessen, Germany
KENNETH LUNDSTROM • PanTherapeutics, Lutry, Switzerland
ZBIGNIEW MADEJA • Department of Cell Biology, Faculty of Biochemistry, Biophysics and
Biotechnology, Jagiellonian University, Krak ow, Poland
PAMELA MANCHA-AGRESTI • Laboratory of Cellular and Molecular Genetics (LGCM),
Department of Genetics, Ecology and Evolution, Institute of Biological Sciences, Federal
University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil; Biomedical
Science Institute (ICBM), Catholic of Cuyo University, San Juan, CP, Argentina
MICHAEL J. MCCLUSKIE • Human Health Therapeutics, National Research Council
Canada, Ottawa, ON, Canada
PAUL F. MCKAY • Section of Immunology of Infection, Department of Infectious Disease,
Imperial College London, London, UK
FRANCESCA MICOLI • GSK Vaccines Institute for Global Health, Siena, Italy
CHAEHO MOON • Division of Molecular Pharmaceutics and Drug Delivery, College of
Pharmacy, The University of Texas at Austin, Austin, TX, USA
ROOZBEH NAYERHODA • Department of Biomedical Engineering, University at Buffalo, The
State University of New York at Buffalo, Buffalo, NY, USA
KATHRYN K. OI • Institute of Microbiology, ETH Zurich, Zurich, Switzerland
NIKOLAI PETROVSKY • Vaxine Pty Ltd, Warradale, SA, Australia; College of Medicine and
Public Health, Flinders University, Adelaide, SA, Australia
BLAINE A. PFEIFER • Department of Chemical and Biological Engineering, University at
Buffalo, The State University of New York, Buffalo, NY, USA
CHRISTOPHER L. PINDER • Section of Immunology of Infection, Department of Infectious
Disease, Imperial College London, London, UK
RUIQUAN QI • Department of Chemical and Biological Engineering, University at Buffalo,
The State University of New York at Buffalo, Buffalo, NY, USA
HUI QIAN • Nanotechnology Research Center, National Research Council Canada,
Edmonton, AB, Canada
MONIKA RAK • Department of Cell Biology, Faculty of Biochemistry, Biophysics and
Biotechnology, Jagiellonian University, Krak ow, Poland
SUWIPA RAMPHAN • Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom,
Thailand
JOSHUA D. RAMSEY • School of Chemical Engineering, Oklahoma State University, Stillwater,
OK, USA
KEYA L. RODRIGUES • LumaCyte, LLC, Charlottesville, VA, USA
DENISE SALZIG • Institute of Bioprocess Engineering and Pharmaceutical Technology (IBPT),
Technische Hochschule Mittelhessen (THM) - University of Applied Sciences, Giessen,
Germany
ROBIN J. SHATTOCK • Section of Immunology of Infection, Department of Infectious Disease,
Imperial College London, London, UK
PRATYOOSH SHUKLA • Enzyme Technology and Protein Bioinformatics Laboratory,
Department of Microbiology, Maharshi Dayanand University Rohtak, Rohtak, Haryana,
India
xiv
Contributors
(IBPT), Technische Hochschule Mittelhessen (THM) - University of Applied Sciences,
Giessen, Germany
KEVEN LOTHERT • Institute of Bioprocess Engineering and Pharmaceutical Technology
(IBPT), Technische Hochschule Mittelhessen (THM) - University of Applied Sciences,
Giessen, Germany
KENNETH LUNDSTROM • PanTherapeutics, Lutry, Switzerland
ZBIGNIEW MADEJA • Department of Cell Biology, Faculty of Biochemistry, Biophysics and
Biotechnology, Jagiellonian University, Krak ow, Poland
PAMELA MANCHA-AGRESTI • Laboratory of Cellular and Molecular Genetics (LGCM),
Department of Genetics, Ecology and Evolution, Institute of Biological Sciences, Federal
University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil; Biomedical
Science Institute (ICBM), Catholic of Cuyo University, San Juan, CP, Argentina
MICHAEL J. MCCLUSKIE • Human Health Therapeutics, National Research Council
Canada, Ottawa, ON, Canada
PAUL F. MCKAY • Section of Immunology of Infection, Department of Infectious Disease,
Imperial College London, London, UK
FRANCESCA MICOLI • GSK Vaccines Institute for Global Health, Siena, Italy
CHAEHO MOON • Division of Molecular Pharmaceutics and Drug Delivery, College of
Pharmacy, The University of Texas at Austin, Austin, TX, USA
ROOZBEH NAYERHODA • Department of Biomedical Engineering, University at Buffalo, The
State University of New York at Buffalo, Buffalo, NY, USA
KATHRYN K. OI • Institute of Microbiology, ETH Zurich, Zurich, Switzerland
NIKOLAI PETROVSKY • Vaxine Pty Ltd, Warradale, SA, Australia; College of Medicine and
Public Health, Flinders University, Adelaide, SA, Australia
BLAINE A. PFEIFER • Department of Chemical and Biological Engineering, University at
Buffalo, The State University of New York, Buffalo, NY, USA
CHRISTOPHER L. PINDER • Section of Immunology of Infection, Department of Infectious
Disease, Imperial College London, London, UK
RUIQUAN QI • Department of Chemical and Biological Engineering, University at Buffalo,
The State University of New York at Buffalo, Buffalo, NY, USA
HUI QIAN • Nanotechnology Research Center, National Research Council Canada,
Edmonton, AB, Canada
MONIKA RAK • Department of Cell Biology, Faculty of Biochemistry, Biophysics and
Biotechnology, Jagiellonian University, Krak ow, Poland
SUWIPA RAMPHAN • Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom,
Thailand
JOSHUA D. RAMSEY • School of Chemical Engineering, Oklahoma State University, Stillwater,
OK, USA
KEYA L. RODRIGUES • LumaCyte, LLC, Charlottesville, VA, USA
DENISE SALZIG • Institute of Bioprocess Engineering and Pharmaceutical Technology (IBPT),
Technische Hochschule Mittelhessen (THM) - University of Applied Sciences, Giessen,
Germany
ROBIN J. SHATTOCK • Section of Immunology of Infection, Department of Infectious Disease,
Imperial College London, London, UK
PRATYOOSH SHUKLA • Enzyme Technology and Protein Bioinformatics Laboratory,
Department of Microbiology, Maharshi Dayanand University Rohtak, Rohtak, Haryana,
India
xiv
Contributors